Analyst Brief July 20, 2026

H.R. 3029 — Nucleic Acid Standards for Biosecurity Act, as amended

Current Status

Suspension Calendar

Executive Summary

H.R. 3029, the 'Nucleic Acid Standards for Biosecurity Act,' directs the National Institute of Standards and Technology (NIST) to develop best practices, guidelines, and technical standards for biosecurity risk management in engineering biology, specifically focusing on nucleic acid synthesis and AI-related risks. The bill mandates the creation of a public-private stakeholder consortium to establish consensus priorities for synthetic nucleic acid procurement screening and requires a report to Congress within 18 months. It authorizes $5 million annually from FY2027 to FY2031 to support these efforts, aiming to mitigate the national security risks of engineered pathogens while supporting the growing U.S. bioeconomy.

Bill Data

Primary Sponsor

Rep. Andrea Salinas (D-OR)

Bill Number

H.R. 3029

Session

119th

Co-Sponsors

Rep. Rich McCormick (R-GA)
View on Congress.gov ↗

Arguments For

  • Argument 1: Addresses a critical, emerging national security vulnerability by establishing standards to prevent malicious actors from exploiting synthetic biology and AI to create engineered pathogens.
  • Argument 2: Fosters a collaborative, industry-friendly approach by utilizing a public-private consortium rather than imposing heavy-handed, top-down regulatory mandates on the bio-manufacturing sector.
  • Argument 3: Represents a relatively low-cost ($25M over 5 years) but high-leverage investment in U.S. economic competitiveness and biosecurity infrastructure.

Likely Supporters

Biotechnology Innovation Organization (BIO)Nuclear Threat Initiative (NTI) BioGinkgo BioworksNational Security Innovation Network

Arguments Against

  • Argument 1: Fiscal hawks may object to authorizing new discretionary spending, even at the relatively low level of $5 million per year.
  • Argument 2: Some industry stakeholders might fear that 'best practices' and 'guidelines' developed by NIST will inevitably become de facto mandatory regulations, increasing compliance costs for synthetic DNA providers.

Likely Opponents

Hardline fiscal conservative groups

📋 Key Provisions

  • Mandates NIST to develop technical standards and best practices for risk management in engineering biology, explicitly including risks associated with artificial intelligence.
  • Directs research into improving the accuracy, efficacy, and reliability of nucleic acid synthesis screening and managing sequence-of-concern databases.
  • Establishes a public-private consortium of industry, academia, and nonprofits to develop consensus priorities for synthetic nucleic acid procurement screening mechanisms.
  • Requires a report to the Senate Commerce and House Science committees within 18 months of the consortium's first meeting.
  • Authorizes $5,000,000 annually for FY2027 through FY2031 for NIST to conduct this research and support the consortium.
search Verification Guide BETA expand_more

Don't trust AI? Don't worry, neither do I. Verify the claims yourself.

Claim Analysis Page 4, Line 17

Authorizes $5 million annually for fiscal years 2027 through 2031.

Verify Text

"thorized to be appropriated $5,000,000"

Claim Analysis Page 4, Line 5

Requires a report to Congress within 18 months of the first consortium meeting.

Verify Text

"Not later than 18 months after"

Claim Analysis Page 2, Line 16

Explicitly addresses risks associated with artificial intelligence in biomanufacturing.

Verify Text

"including risks associated with the use of artifi"